<DOC>
	<DOCNO>NCT00225212</DOCNO>
	<brief_summary>Conventional therapy effective diffuse aggressive lymphoma low grade lymphoma , limited relapse occur 40 50 % subject . This study assess autologous stem cell transplant ( ASCT ) supplement high-dose therapy increase event-free survival diffuse aggressive lymphoma low grade lymphoma , alternative limitation conventional therapy . Preliminary study rituximab low grade lymphoma indicate response rate 50 % little toxicity . Rituximab hypothesize candidate post-transplant therapy majority malignant lymphoma express CD20 antigen ; rituximab impressive independent anti-tumor activity ; antibody little toxicity outside acute administration .</brief_summary>
	<brief_title>Rituximab After Autologous Stem Cell Transplant Relapsed B-cell Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>The first 4 subject receive rituximab weekly 4 week standard dose 375 mg/m2 , start 6 week ASCT transplant . After observation period ass acute late toxicity first 4 subject , subsequent subject receive induction follow additional 4 week course 6-months post-ASCT .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Bcell , CD20+ NHL Evidence engraftment postautologous peripheral blood stem cell transplant ( PBSCT ) , aka autologous stem cell transplant ( ASCT ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Creatinine &lt; 2 mg/dL Bilirubin &lt; 2.0 mg/dL Liver function test ( LFTs ) &lt; 5 x upper limit normal ( ULN ) Graft source bone marrow Nonresponders [ progressive disease ( PD ) stable disease ( SD ) ] prior antiCD20 therapy PD ASCT PostASCT radiotherapy Concomitant treatment radiotherapy , chemotherapy immunotherapy include rituximab Evidence active pneumonitis Evidence active infection Concurrent prednisone systemic steroid medication Nitrosourea therapy within 6 week first treatment rituximab Presence antimurine antibody ( HAMA ) reactivity</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>non-Hodgkin 's lymphoma</keyword>
	<keyword>diffuse large cell lymphoma</keyword>
	<keyword>mantle cell lymphoma</keyword>
	<keyword>transform lymphoma</keyword>
	<keyword>subtypes B cell lymphoma</keyword>
	<keyword>recurrent lymphoma</keyword>
</DOC>